Trial Profile
Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda in Mexican Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Nov 2022
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 10 Nov 2022 Status changed from recruiting to completed.
- 27 Apr 2021 Planned End Date changed from 29 Jan 2021 to 30 Nov 2021.
- 27 Apr 2021 Planned primary completion date changed from 29 Jan 2021 to 30 Nov 2021.